MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MBX - CA59501P1045 - Common Stock
0.24 CAD
+0.01 (+4.35%)
Overall MBX gets a fundamental rating of 4 out of 10. We evaluated MBX against 22 industry peers in the Biotechnology industry. MBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MBX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MBX has reported negative net income.
In the past year MBX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of -6.00%, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
MBX has a better Return On Equity (-8.08%) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROIC | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 53.02%, MBX belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
In the last couple of years the Gross Margin of MBX has grown nicely.
The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
2. Health
2.1 Basic Checks
MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MBX has more shares outstanding
The number of shares outstanding for MBX has been increased compared to 5 years ago.
MBX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.77, we must say that MBX is in the distress zone and has some risk of bankruptcy.
MBX has a Altman-Z score of 1.77. This is amongst the best in the industry. MBX outperforms 86.36% of its industry peers.
A Debt/Equity ratio of 0.24 indicates that MBX is not too dependend on debt financing.
MBX has a Debt to Equity ratio (0.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.77 |
ROIC/WACCN/A
WACC7.45%
2.3 Liquidity
A Current Ratio of 8.48 indicates that MBX has no problem at all paying its short term obligations.
MBX's Current ratio of 8.48 is amongst the best of the industry. MBX outperforms 90.91% of its industry peers.
A Quick Ratio of 5.17 indicates that MBX has no problem at all paying its short term obligations.
MBX's Quick ratio of 5.17 is amongst the best of the industry. MBX outperforms 86.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -163.28% in the last year.
The Revenue for MBX has decreased by -26.81% in the past year. This is quite bad
The Revenue has been growing by 12.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
3.2 Future
MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.75% yearly.
MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MBX is valuated cheaply with a Price/Forward Earnings ratio of 5.94.
Based on the Price/Forward Earnings ratio, MBX is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
MBX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaper than 95.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 146.32 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 52.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MBX (1/2/2026, 7:00:00 PM)
0.24
+0.01 (+4.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap33.36M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 | ||
| P/S | 1.79 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.2 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 146.32 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY16.83%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% | ||
| FCFM | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 34.25 | ||
| Cap/Depr | 44.81% | ||
| Cap/Sales | 4.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 1.77 |
F-Score2
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.
What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.